<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Staphylococcal scalded skin syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Staphylococcal scalded skin syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Staphylococcal scalded skin syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick McMahon, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2988193692"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Staphylococcal scalded skin syndrome (SSSS) is a bacterial toxin-mediated skin disorder that primarily affects young children but can also occur in older children and adults. Previous terms for SSSS in newborn infants include Ritter's disease and pemphigus neonatorum.</p><p>SSSS occurs when exotoxins produced by <em>Staphylococcus aureus</em> undergo hematogenous dissemination to the skin  (<a class="graphic graphic_figure graphicRef121147" href="/d/graphic/121147.html" rel="external">figure 1</a>). The characteristic clinical findings include diffuse skin pain and erythema as well as superficial blistering and desquamation  (<a class="graphic graphic_picture graphicRef121025 graphicRef121026 graphicRef121027 graphicRef72261 graphicRef121041 graphicRef80198 graphicRef121028 graphicRef50249" href="/d/graphic/121025.html" rel="external">picture 1A-H</a>). Common associated findings include fever, irritability, and poor oral intake. </p><p>Patients with SSSS typically require hospital admission for intravenous antibiotic therapy and supportive care. When adequately treated, the prognosis is excellent. Most patients recover fully within two to three weeks without significant scarring, disfigurement, or other long-term sequelae.</p><p>The clinical features, diagnosis, and management of SSSS will be reviewed here. Other cutaneous manifestations of <em>S. aureus</em> infection are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7655.html" rel="external">"Impetigo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Bacterial folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p></p><p class="headingAnchor" id="H2825537071"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SSSS primarily affects young children. SSSS in adults is less frequent and usually occurs in the setting of serious illness. </p><p>SSSS in children most often occurs before the age of six and has been reported as early as the first day of life [<a href="#rid1">1,2</a>]. Estimates of the incidence of SSSS vary. An analysis of data from over 6 million pediatric hospital stays in the United States between 2008 and 2012 supports a mean annual incidence of approximately 8 cases per million children and approximately 45 cases per million children under the age of two years [<a href="#rid3">3</a>].</p><p>The major risk factors for SSSS in adults include impaired kidney function, immunosuppression, and other comorbidities that impair the immune response to bacterial infection (eg, diabetes) [<a href="#rid4">4,5</a>]. An analysis of over 32 million hospitalizations in adults in the United States between 2008 and 2012 supports an annual incidence of approximately 1 case per million adults [<a href="#rid6">6</a>]. The incidence increased with age, from 0.3 cases per million for adults between the ages of 18 and 39 years to 3.91 cases per million for adults over the age of 80 years.</p><p>Studies assessing the sex ratio in SSSS have yielded inconsistent results. Whereas a study of 399 children with SSSS in the Czech Republic found SSSS more frequent in males, a study of hospital data from the United States found SSSS more common in females [<a href="#rid3">3,7</a>].</p><p>There may be seasonal variation in the incidence of SSSS. Peak incidences in the summer and autumn for childhood SSSS have been found in some studies [<a href="#rid3">3,8</a>]. </p><p class="headingAnchor" id="H3190319300"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>SSSS is caused by exotoxin-producing strains of <em>S. aureus</em>, with the most common subsets being phage group 2 strains 55 and 71. Less common causative strains include types 3A, 3B, 3C, and the ST121 strain. </p><p>The two pathogenic toxins produced in SSSS are exfoliative (or epidermolytic) toxin A (ETA) and exfoliative toxin B (ETB). <em>S. aureus</em> strains implicated in SSSS may produce ETA, ETB, or both toxins [<a href="#rid9">9</a>]. Approximately 5 percent of all <em>S. aureus</em> isolates and approximately 95 percent of the ST121 strain produce these toxins [<a href="#rid10">10,11</a>]. </p><p>The pathogenic exotoxins serve as serine protease enzymes that cleave desmoglein 1, a desmosomal linking protein responsible for keratinocyte-to-keratinocyte adhesion in the stratum granulosum. Hematogenous dissemination of the exotoxins from the initial focus of <em>S. aureus</em> infection stimulates separation of epidermal keratinocytes and detachment of the superficial epidermis  (<a class="graphic graphic_figure graphicRef121147" href="/d/graphic/121147.html" rel="external">figure 1</a>). (See <a class="local">'Clinical features'</a> below.)</p><p>The frequent occurrence of prodromal symptoms resembling upper respiratory viral infections (eg, fever, irritability) has led some authors to suggest a role for viral infection as a promoter of proliferation of exotoxin-producing strains of <em>S. aureus </em>[<a href="#rid9">9</a>]. However, this theory has not been confirmed.</p><p class="headingAnchor" id="H2368246273"><span class="h1">ACQUISITION</span><span class="headingEndMark"> — </span>SSSS typically arises from a focus of infection with an exotoxin-producing <em>S. aureus</em> strain, such as may occur in impetigo, bacterial conjunctivitis, or iatrogenic wounds. SSSS may also occur in the setting of infections such as staphylococcal pneumonia, pyomyositis, septic arthritis, or endocarditis [<a href="#rid12">12</a>]. Rare reports indicate staphylococcal mastitis as a maternal source of infection for breastfed newborns [<a href="#rid13">13</a>]. The incubation period from <em>S. aureus</em> infection to SSSS usually ranges from 1 to 10 days [<a href="#rid10">10</a>].</p><p>Transmission of exotoxin-producing strains of <em>S. aureus</em> can occur between individuals, including from asymptomatic, colonized individuals. Outbreaks of SSSS have occurred in newborn nurseries and intensive care units [<a href="#rid14">14,15</a>]. (See <a class="local">'Prevention'</a> below.)</p><p>The susceptibility of young children to SSSS is postulated to result from a lack of protective antibodies against staphylococcal toxins and/or insufficient ability of young children's kidneys to excrete the exotoxins [<a href="#rid4">4</a>]. Adult susceptibility appears to occur in the presence of impaired immunity, impaired renal function, or serious illness. Adult disease is often associated with a high burden of staphylococci. </p><p class="headingAnchor" id="H1523429731"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>SSSS is characterized by progressive, cutaneous erythema and desquamation and constitutional symptoms  (<a class="graphic graphic_picture graphicRef121025 graphicRef121026 graphicRef121027 graphicRef72261 graphicRef121041 graphicRef80198 graphicRef121028 graphicRef50249" href="/d/graphic/121025.html" rel="external">picture 1A-H</a>). The term "scalded skin" refers to the resemblance of acute burns from hot water. Mucous membrane involvement is absent. </p><p class="headingAnchor" id="H1766266346"><span class="h2">Cutaneous findings</span><span class="headingEndMark"> — </span>The earliest cutaneous signs of SSSS are macular erythema and skin pain. Initially, erythema is accentuated in the skin folds, such as the neck, axillae, inguinal folds, and gluteal cleft. The erythema may be subtle, can wax and wane, and may be especially difficult to appreciate in patients with highly pigmented skin. Generalized erythema usually develops within 48 hours. </p><p>As the disease progresses, flaccid bullae begin to appear in areas of skin erythema, resulting in a wrinkled appearance  (<a class="graphic graphic_picture graphicRef80198" href="/d/graphic/80198.html" rel="external">picture 1F</a>). Shallow erosions may also occur in sites subject to friction, such as in the perianal region. Even minor insults, such as placement of a blood pressure cuff or removal of adhesive tape, may lead to erosions. Sheet-like, superficial desquamation can develop, leaving large patches of moist, erythematous, shiny skin.</p><p>Thick crusting and radial fissuring often develops around the mouth, nose, and eyes  (<a class="graphic graphic_picture graphicRef121028" href="/d/graphic/121028.html" rel="external">picture 1G</a>). The crusting, fissuring, and associated erythema can be striking and is classically referred to as SSSS "sad face." The perioral crusting has been likened to dried oatmeal in its appearance.</p><p class="headingAnchor" id="H1770113200"><span class="h2">Associated signs and symptoms</span><span class="headingEndMark"> — </span>Common prodromal and concurrent symptoms include skin pain, fever, irritability, malaise, and poor feeding. As a result of the compromised skin barrier in SSSS, patients can also exhibit signs and symptoms related to significant fluid loss and temperature instability. (See  <a class="medical medical_review" href="/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a> and  <a class="medical medical_review" href="/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults"</a>.)</p><p class="headingAnchor" id="H1383902204"><span class="h2">Primary site of infection</span><span class="headingEndMark"> — </span>The site of staphylococcal infection often is not evident [<a href="#rid10">10</a>]. Findings suggestive of infection include purulent drainage at the conjunctivae and medial canthi of the eyes in conjunctivitis; impetigo-associated, honey-colored crusting of the nares, perinasal skin, or perioral skin; perianal erythema; and pustules or other crusted areas on the skin. In newborns, staphylococcal infection may appear as erosions, purulence, or crusting surrounding the umbilical stump or a recent circumcision site [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1989433962"><span class="h1">COURSE AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Cutaneous erythema and pain typically subside significantly within two to three days after the start of treatment. Erosions and crusted regions usually exhibit significant improvement within one to two weeks.</p><p>Patients can continue to have pain, erythema, and skin peeling for several days despite appropriate antibiotic treatment. The prolongation of symptoms may be due to the persistence of toxins in the blood and<strong><em> </em></strong>tends be most prolonged in neonates. This may be related to relatively inefficient renal clearance or lower immunity to staphylococcal bacteria in neonates [<a href="#rid17">17</a>]. </p><p>Postinflammatory hyperpigmentation or hypopigmentation occasionally follows healing, particularly in patients with highly pigmented skin (eg, phototypes IV to VI  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>)). Pigmentary changes usually fade within several months. Scarring typically does not occur. (See  <a class="medical medical_review" href="/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p>Serious complications are related to the extensive loss of skin and include secondary infection, septicemia, hypovolemia, electrolyte imbalance, and death. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2880046823"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histopathologic examination of a blister in SSSS demonstrates subcorneal cleavage. Acantholysis also may be evident. Inflammatory infiltrates in the dermis are usually absent [<a href="#rid4">4</a>]. Given the fragile nature of the blisters in SSSS, disruption of the epidermal architecture may occur during the biopsy or tissue processing. (See <a class="local">'Histopathologic examination'</a> below.)</p><p class="headingAnchor" id="H2401085884"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of SSSS usually can be made based upon the history and physical findings. Bacterial cultures of sites of suspected staphylococcal infection should also be performed to confirm <em>S. aureus</em> infection and provide information on antibiotic susceptibility. Histopathologic examination can confirm SSSS in challenging cases.</p><p class="headingAnchor" id="H4094404512"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>The clinical assessment includes a focused history and an examination of the entire skin surface and mucous membranes. The goals are to identify findings consistent (or inconsistent) with SSSS and to detect the site of <em>S. aureus</em> infection. (See <a class="local">'Clinical features'</a> above.)</p><p>The patient history should review the course of skin disease, associated symptoms, and the medical history. Examples of findings supportive of SSSS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Occurrence in either a young child or an older child/adult with an impaired immune system, impaired renal function, or serious illness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial onset of erythema in skin folds followed by rapid progression to widespread erythema (eg, within 48 hours)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated skin pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prodrome or concurrent fever, irritability, or poor oral intake</p><p></p><p>Examination of the skin and mucous membranes should be performed with care to avoid unnecessary friction-induced erosions and to minimize pain. Careful inspection in a well-lit environment is essential for assessing macular erythema. Physical findings consistent with SSSS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive, blanchable skin erythema</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flaccid bullae, superficial desquamation, and shallow erosions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absent mucous membrane involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of concurrent cutaneous, conjunctival, or internal staphylococcal infection (see <a class="local">'Primary site of infection'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive Nikolsky sign</p><p></p><p>The Nikolsky sign describes blistering or sloughing of skin in response to gentle mechanical pressure. While helpful for identifying skin fragility consistent with SSSS, attempts to elicit this sign can be painful, and a positive Nikolsky sign may also occur in conditions other than SSSS. Recognition of clues, such as a history of blister and erosion formation at sites of minor skin insults, can eliminate the need to intentionally induce an erosion. (See  <a class="medical medical_review" href="/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Nikolsky sign'</a> and <a class="local">'Cutaneous findings'</a> above.)</p><p>Unlike conditions associated with full-thickness detachment of the epidermis, such as toxic epidermal necrolysis (TEN), erosions in SSSS are less likely to exhibit pinpoint bleeding. This is related to the superficial level of blistering.</p><p class="headingAnchor" id="H1668979818"><span class="h2">Histopathologic examination</span><span class="headingEndMark"> — </span>Histopathologic examination is not required for diagnosis but can confirm the diagnosis through distinguishing SSSS from other causes of skin blistering or sloughing when diagnostic uncertainty remains despite a careful history and physical examination. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Options for obtaining histologic support for SSSS include sampling of the full thickness of the epidermis and superficial dermis with a shave or punch biopsy and obtaining a piece of sloughed epidermis for examination. The primary goal of both procedures is to identify the level of epidermal cleavage and differentiate SSSS from conditions in which cleavage occurs lower in the epidermis or in the subepidermal plane (eg, TEN). </p><p>The specimen can be placed in formalin and submitted for routine histologic processing or placed on saline-moistened gauze and transported immediately to a pathology laboratory for examination as a frozen section. Generally, a skin biopsy submitted for routine histologic processing is the preferred procedure, particularly when there is greater uncertainty regarding the diagnosis, as it allows for a more complete pathologic assessment than examination of sloughed skin or frozen sections. The major advantage of frozen sections is rapid availability of results, when needed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shave or punch biopsy</strong> – Shave and punch biopsies should be taken from the edge of an intact vesicle or bulla. For punch biopsies, a diameter of 4 mm is usually sufficient. The classic finding is a subcorneal split in the epidermis. (See  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Snip biopsy </strong>– A snip biopsy involves the removal of a small piece of freshly sloughed epidermis. This procedure may be preferable for small children or neonates when a full biopsy is likely to be challenging or poorly tolerated. Specimens of sloughed skin from SSSS demonstrate only the uppermost portion of the epidermis. </p><p></p><p class="headingAnchor" id="H2189639856"><span class="h2">Bacterial cultures</span><span class="headingEndMark"> — </span>Although the site of <em>S. aureus </em>infection cannot always be found, a culture that confirms <em>S. aureus </em>infection supports the diagnosis of SSSS. Because blistering in SSSS results from hematologic dissemination of staphylococcal exotoxins rather than local infection, intact blisters in SSSS are sterile, and culture of blisters will not yield the causative organism.</p><p>Cultures should be taken from cutaneous or mucosal sites of suspected primary infection (eg, areas of purulent drainage) identified during a physical examination or, in the absence of an obvious site of infection, from a common site of <em>S. aureus</em> colonization (eg, nares) [<a href="#rid9">9</a>]. Common sites for culture are the skin, conjunctivae, nares, ear canals, and nasopharynx. In a French retrospective study of 212 children with SSSS, toxin-producing<em> S. aureus</em> was isolated from skin lesions (56 percent); nose, throat, eyes, or ears (35 percent); blood (4 percent); and stool (1 percent) [<a href="#rid9">9</a>]. Antibiotic susceptibility testing should also be performed to facilitate treatment selection. (See <a class="local">'Primary site of infection'</a> above and <a class="local">'Antibiotic therapy'</a> below.)</p><p>Routine performance of blood cultures is not necessary in otherwise healthy children but may be appropriate in children at risk for bacteremia, such as a febrile neonate, immunocompromised child, or child with a serious illness. It is estimated that less than 5 percent of hospitalized pediatric patients with SSSS have bacteremia or sepsis [<a href="#rid2">2,9</a>]. </p><p>In contrast to children, <em>S. aureus</em> bacteremia is relatively common in adults with SSSS [<a href="#rid4">4,6</a>]. Thus, blood cultures should be obtained in adults. </p><p class="headingAnchor" id="H2018808760"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of SSSS includes other infections, inflammatory conditions, and toxicities that present with extensive, cutaneous erythema or blistering.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burns</strong> – Chemical burns, thermal burns, or sunburn may result in erythema, blistering, and/or sloughing of the skin that can mimic SSSS  (<a class="graphic graphic_picture graphicRef109270 graphicRef52112" href="/d/graphic/109270.html" rel="external">picture 2A-B</a>). The history of an insult to the skin that corresponds to the distribution of the skin changes differentiates burns from other blistering conditions. (See  <a class="medical medical_review" href="/d/html/819.html" rel="external">"Assessment and classification of burn injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous impetigo</strong> – Bullous impetigo is a superficial skin infection caused by the same toxin-producing strains of <em>S. aureus</em> associated with SSSS. Bullous impetigo most often occurs in young children and presents with vesicles, flaccid bullae, and erosions with collarettes of scale at sites of ruptured bullae  (<a class="graphic graphic_picture graphicRef101462 graphicRef96269" href="/d/graphic/101462.html" rel="external">picture 3A-B</a>). Intertriginous involvement is common. In contrast to SSSS, toxins are localized to the sites of skin infections rather than hematologically spread, and cultures of bullae will demonstrate <em>S. aureus</em>. Of note, bullous impetigo may progress to SSSS. (See  <a class="medical medical_review" href="/d/html/7655.html" rel="external">"Impetigo", section on 'Bullous impetigo'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stevens-Johnson syndrome and toxic epidermal necrolysis</strong> – Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe blistering eruptions that involve the skin and mucous membranes  (<a class="graphic graphic_picture graphicRef59418 graphicRef73805" href="/d/graphic/59418.html" rel="external">picture 4A-B</a>). Targetoid skin lesions, fever, and skin pain are common associated findings. Medications are the most common cause of SJS and TEN, followed by infections. A biopsy is helpful for supporting the diagnosis; in contrast to the superficial blistering in SSSS, SJS and TEN demonstrate subepidermal blistering and full-thickness epidermal necrosis resulting in deeper erosions. In addition, mucosal involvement is present in SJS and TEN but absent in SSSS. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic shock syndrome</strong> – Streptococcal and staphylococcal toxic shock syndromes are toxin-mediated systemic bacterial infections that can mimic SSSS. The inciting infections are usually a localized abscess, pyomyositis, or superinfection of a retained foreign body, such as tampons or surgical packing. Typical findings include widespread, blanchable, cutaneous erythema; conjunctival injection; "strawberry tongue;" fever; and hypotension  (<a class="graphic graphic_picture graphicRef61786" href="/d/graphic/61786.html" rel="external">picture 5</a>). Unlike SSSS, there is a lack of periorificial crusting on the face, absent bullae or desquamation, and a negative Nikolsky sign. Acral skin peeling or desquamation can occur but usually appears several days after the onset of symptoms [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a> and  <a class="medical medical_review" href="/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis", section on 'Toxic shock syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scarlet fever</strong> – Scarlet fever is a bacterial infection caused by Group A <em>Streptococcus</em> that causes fever and a widespread cutaneous eruption and most often occurs in children in association with streptococcal pharyngitis. Affected individuals develop a "sandpaper-like" cutaneous eruption composed of diffuse, fine, pinpoint papules that are skin colored or slightly erythematous, which is followed by desquamation  (<a class="graphic graphic_picture graphicRef82758 graphicRef58805" href="/d/graphic/82758.html" rel="external">picture 6A-B</a>). The perioral crusting, skin fragility, and skin pain seen in SSSS are absent in scarlet fever. The diagnosis of scarlet fever is made based upon clinical manifestations. Confirmation of streptococcal infection supports the diagnosis. (See  <a class="medical medical_review" href="/d/html/8046.html" rel="external">"Complications of streptococcal tonsillopharyngitis", section on 'Scarlet fever'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kawasaki disease</strong> – The cutaneous manifestations of Kawasaki disease are polymorphous and can include erythema accentuated in the flexural regions similar to early SSSS  (<a class="graphic graphic_picture graphicRef91532" href="/d/graphic/91532.html" rel="external">picture 7</a>). Affected patients will also typically have fever, conjunctivitis, "strawberry tongue," cervical lymphadenopathy, and swelling of their hands and feet. Kawasaki disease may manifest with superficial desquamation in localized areas (eg, inguinal folds) but does not typically have the positive Nikolsky sign, skin fragility, skin pain, or perioral crusting associated with SSSS [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/6417.html" rel="external">"Kawasaki disease: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus</strong> – Pemphigus foliaceus and pemphigus vulgaris are autoimmune blistering disorders that may present with widespread blistering and erosions. Similar to SSSS, pemphigus foliaceus involves targeting of desmoglein 1, resulting in superficial blistering and an absence of mucosal involvement  (<a class="graphic graphic_picture graphicRef87795" href="/d/graphic/87795.html" rel="external">picture 8</a>). In pemphigus vulgaris, desmoglein 3 is the targeted antigen and blistering occurs lower in the epidermis, resulting in deeper erosions and characteristic mucosal erosions  (<a class="graphic graphic_picture graphicRef63170 graphicRef56333" href="/d/graphic/63170.html" rel="external">picture 9A-B</a>). A skin biopsy with direct immunofluorescence microscopy is used to confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Clinical features'</a>.)</p><p></p><p>Examples of additional disorders that should be considered in neonates include the blistering disorders epidermolysis bullosa  (<a class="graphic graphic_picture graphicRef68938" href="/d/graphic/68938.html" rel="external">picture 10</a>), epidermolytic ichthyosis  (<a class="graphic graphic_picture graphicRef90570" href="/d/graphic/90570.html" rel="external">picture 11</a>), and bullous mastocytosis  (<a class="graphic graphic_picture graphicRef63556" href="/d/graphic/63556.html" rel="external">picture 12</a>). Unlike SSSS, these disorders are not associated with fever in the absence of secondary or unrelated infection. In addition, cutaneous candidiasis in neonates may present with widespread erythema, papules, pustules, and desquamation and should be considered in the differential diagnosis  (<a class="graphic graphic_picture graphicRef118658 graphicRef94975" href="/d/graphic/118658.html" rel="external">picture 13A-B</a>). Broader discussions of the differential diagnosis of neonatal blistering and <em>Candida</em> infection in neonates are available separately. (See  <a class="medical medical_review" href="/d/html/5790.html" rel="external">"Vesicular, pustular, and bullous lesions in the newborn and infant", section on 'Congenital/inherited disorders'</a> and  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a>.)</p><p>Poisoning is an infrequent cause of SSSS-like skin changes. Ingestion or topical exposure of boric acid, an ingredient in pesticides, household cleaning agents, and some preparations of homemade slime, may cause an erythematous, desquamative rash that can mimic SSSS, toxic shock syndrome, or TEN [<a href="#rid20">20-22</a>]. Other exposures that may mimic SSSS include mercury poisoning (acral erythema and superficial peeling of skin) [<a href="#rid23">23</a>] and perianal burn-like desquamation and erythema following ingestion and excretion of sennoside-containing laxatives, particularly in diapered infants [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H2222860822"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of SSSS involves eradication of the causative staphylococcal infection and supportive care to promote healing, reduce discomfort, and minimize complications. Patients are typically hospitalized for treatment [<a href="#rid2">2,3</a>]. Treatment is recommended for all patients with SSSS.</p><p class="headingAnchor" id="H3754140606"><span class="h2">Immediate interventions</span><span class="headingEndMark"> — </span>Immediate interventions for SSSS generally include hospital admission, intravenous antibiotic therapy, and the initiation of supportive measures.</p><p class="headingAnchor" id="H17515901"><span class="h3">Admission to hospital</span><span class="headingEndMark"> — </span>Children and adults with SSSS are usually treated in an inpatient setting. Patients with SSSS should be admitted to a location in which careful, appropriate skin care can be implemented. In some hospitals, this may require admission to a burn unit or intensive care unit. (See <a class="local">'Supportive care'</a> below.)</p><p>In settings where adequate skin care can be provided outside of an intensive care unit or burn unit, most children do not require admission to an intensive care unit [<a href="#rid2">2</a>]. A typical hospital stay for children lasts three to eight days [<a href="#rid2">2,3</a>]. In contrast, most adults with SSSS are seriously ill, and comorbidities or complications may warrant admission to an intensive care unit.</p><p class="headingAnchor" id="H3036907301"><span class="h3">Antibiotic therapy</span><span class="headingEndMark"> — </span>Intravenous treatment with an antistaphylococcal antibiotic should begin promptly. Patients are typically initially treated with a penicillinase-resistant penicillin, such as <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a> or <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>. Initial antibiotic selection should be subsequently adjusted based upon antimicrobial susceptibility of isolates. In addition, antibiotic selection and dosing should be appropriately adjusted based upon the underlying infection. (See <a class="local">'Treatment course'</a> below and  <a class="medical medical_review" href="/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p>Alternatives for initial treatment include a first- or second-generation cephalosporin or <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>. As with penicillinase-resistant penicillins, treatment should be subsequently adjusted, if needed.</p><p><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> has antistaphylococcal activity but is not recommended as a primary treatment because of high rates of clindamycin resistance in SSSS [<a href="#rid25">25,26</a>]. Although some clinicians add clindamycin as an adjunct to a penicillinase-resistant penicillin or cephalosporin based upon the theory that clindamycin may decrease ribosomal production of the pathogenic staphylococcal exotoxins or from concern for resistance to antistaphylococcal penicillins [<a href="#rid25">25,27</a>], evidence to support superior efficacy of this practice is lacking. We do not typically add clindamycin to standard antibiotic therapy. We occasionally add clindamycin in the setting of a severely ill patient. (See <a class="local">'Treatment course'</a> below.)</p><p>Common intravenous antibiotic regimens for children with SSSS associated with a skin or soft tissue infection are listed below. Most SSSS isolates in children are susceptible to <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a> or <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a> [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>nafcillin</strong><strong> or </strong><strong>oxacillin</strong> – 100 to 150 mg/kg per day in divided doses every six hours; maximum daily dose of 12 g per day. Weight-based dosing for neonates differs and is reviewed separately. (See  <a class="drug drug_pediatric" href="/d/drug information/12626.html" rel="external">"Nafcillin: Pediatric drug information"</a> and  <a class="drug drug_pediatric" href="/d/drug information/12663.html" rel="external">"Oxacillin: Pediatric drug information"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>cefazolin</strong> – 50 to 100 mg/kg per day in divided doses every eight hours; usual maximum daily dose of 6 g. (See  <a class="drug drug_general" href="/d/drug information/9214.html" rel="external">"Cefazolin: Drug information"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>vancomycin</strong> – 45 mg/kg per day in divided doses every eight hours; usual maximum daily dose of 2 g. Weight-based dosing for neonates differs and is reviewed separately. (See  <a class="drug drug_pediatric" href="/d/drug information/12874.html" rel="external">"Vancomycin: Pediatric drug information"</a>.)</p><p></p><p class="headingAnchor" id="H855931490"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Supportive care is a critical component of management. Adequate hydration should be ensured, and trauma to the skin should be minimized.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of dehydration</strong> –<strong> </strong>Fluid loss through the skin can be significant in SSSS, and many patients have decreased oral intake of fluids due to irritability, fatigue, and perioral pain. Intravenous hydration is frequently necessary to prevent dehydration and secondary electrolyte abnormalities. (See  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a> and  <a class="medical medical_review" href="/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gentle skin care</strong> – Because even minor trauma to the skin can induce blistering, desquamation, and pain, measures should be taken to minimize direct insults to the skin. Minimal use of adhesives, tourniquets, compression devices, and tape is imperative.</p><p></p><p class="bulletIndent1">Bathing is often avoided for the first 48 hours because of discomfort. Once bathing is resumed, use of a gentle, unscented cleanser is preferred and abrasive scrubbing of the skin should be avoided. After bathing, skin should be patted rather than rubbed dry to minimize skin shearing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound care</strong> – Wound dressings may induce friction and trauma to the skin upon removal and should be limited. For small erosions, frequent application of petroleum jelly is sufficient. Nonadherent dressings, such as petroleum jelly-embedded gauze or self-adherent foam dressings coated with a thick layer of sterile petroleum jelly, can be used to protect large erosions. </p><p></p><p class="bulletIndent1">Dressings should be changed daily. Dressing changes can be painful, and administration of an analgesic prior to dressing changes may be necessary. Children may derive additional benefit from distraction techniques, music therapy, and psychologic support (eg, child-life services).</p><p></p><p class="headingAnchor" id="H75022116"><span class="h2">Treatment course</span><span class="headingEndMark"> — </span>After the start of therapy, culture and antibiotic susceptibility results and the response to treatment should be followed closely. If culture and susceptibility testing reveal an <em>S. aureus</em> strain that is not susceptible to initial therapy (eg, methicillin-resistant <em>Staphylococcus aureus</em> [MRSA]), antibiotic therapy should be adjusted accordingly.</p><p>The prevalences of MRSA and clindamycin-resistant <em>S. aureus</em> vary based upon location. Reported rates of MRSA-induced SSSS and clindamycin-resistant <em>S. aureus</em> in SSSS range from 0 to 69 percent and 26 to 86 percent, respectively [<a href="#rid8">8,25,26,28</a>]. In the author's personal experience in New Jersey and Philadelphia, MRSA-induced SSSS has seemed to account for a minority of cases.</p><p>Once patients demonstrate clinical improvement and are tolerating oral intake, oral antibiotic therapy can replace intravenous antibiotic therapy. The oral antibiotic should be selected based upon the results of antibiotic susceptibility testing.</p><p>The total duration of intravenous and oral treatment with an appropriate antibiotic is typically 10 days. We occasionally extend treatment to 14 days for patients with slow responses (eg, persistent erythema, fever, and progression of skin disease after 7 to 10 days of treatment), such as may occur in young infants. In this scenario, we also optimize intravenous hydration to facilitate removal of toxins. Reassessment to ensure the correct diagnosis is always prudent when patients have poor responses to therapy. (See <a class="local">'Course and complications'</a> above.)</p><p class="headingAnchor" id="H406576385"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Treatment with an antibiotic selected based upon antibiotic susceptibility and supportive measures is typically sufficient, and additional therapy beyond supportive care is not necessary for most patients. Case reports describe rapid improvement following the addition of intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or plasma exchange in patients with severe disease; however, data are insufficient to confirm efficacy of these therapies [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H128052097"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Despite the significant morbidity of SSSS, mortality may be low among children hospitalized for treatment [<a href="#rid2">2,3,6-8,25</a>]. A review of data from pediatric and adult hospitalizations in the United States between 2008 and 2012 found a mortality rate for children of 0.3 percent [<a href="#rid3">3</a>]. </p><p>Reported mortality rates in adults tend to be higher, likely related to the frequent presence of serious comorbidities. A review of data from adult hospitalizations in the United States between 2008 and 2012 found a mortality rate of 4 percent [<a href="#rid6">6</a>]. Higher mortality has also been suggested; a 1994 review of published cases of SSSS found that 19 of 32 adults died soon after diagnosis despite appropriate antibiotic therapy [<a href="#rid31">31</a>]. Mortality is typically related to complications of SSSS, such as sepsis or electrolyte imbalance, or a concurrent disease, such as pneumonia. </p><p>Recurrence of SSSS is rare but does occur, particularly in neonates and young infants [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3744670854"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of SSSS involves minimizing risk for transmission of exotoxin-producing strains of <em>S. aureus</em> to others, particularly young children and other at-risk individuals. These measures are particularly important in newborn nurseries, neonatal intensive care units, and in settings with ill individuals, such as long-term care and inpatient facilities. </p><p>Examples include hand hygiene, trimming nails, and adherence to appropriate precautions in health care settings. The United States Centers for Disease Control and Prevention (CDC) recommends use of both standard and contact precautions for the duration of illness for the care of patients with SSSS [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p><em>S. aureus</em> colonization is common, with up to 40 percent of adults as asymptomatic carriers of <em>S. aureus </em>[<a href="#rid33">33</a>]. In some settings, screening of health care workers and caretakers has been performed to detect the source of SSSS outbreaks [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H2606288974"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110550.html" rel="external">"Society guideline links: Management of <i>Staphylococcus aureus</i> infection"</a>.)</p><p class="headingAnchor" id="H2282914233"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Staphylococcal scalded skin syndrome (SSSS) is a skin disorder that results from infection with exotoxin-producing strains of <em>Staphylococcus aureus</em>. The skin lesions result from hematologic dissemination of exotoxins from the site of infection to the skin. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Acquisition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Young children are most susceptible to SSSS. SSSS in adults usually occurs in the setting of renal impairment, immunosuppression, or other comorbidities that reduce the immune response to bacterial infection. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The causative strains of <em>S. aureus</em> produce exfoliative toxin A and/or exfoliative toxin B, exotoxins capable of cleaving desmoglein 1, a protein responsible for keratinocyte-to-keratinocyte adhesion in the superficial epidermis. Cleavage of desmoglein 1 leads to skin fragility and the formation of superficial blisters and erosions  (<a class="graphic graphic_figure graphicRef121147" href="/d/graphic/121147.html" rel="external">figure 1</a>). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SSSS typically manifests with rapidly progressive, extensive, cutaneous erythema that begins in intertriginous areas. The cutaneous findings progress to include flaccid, sterile bullae; erosions; and sheet-like desquamation. Patients also often develop thick crusting and radial fissuring around the mouth, nose, and eyes, as well as skin pain, fever, irritability, and poor feeding  (<a class="graphic graphic_picture graphicRef121025 graphicRef121026 graphicRef121027 graphicRef72261 graphicRef121041 graphicRef80198 graphicRef121028 graphicRef50249" href="/d/graphic/121025.html" rel="external">picture 1A-H</a>). Mucosal involvement is absent. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of SSSS usually can be made based upon the history and physical examination. Bacterial cultures of sites of suspected <em>S. aureus</em> infection (eg, purulent areas) should be performed to support the diagnosis and provide information on antibiotic susceptibility for treatment. If the diagnosis remains uncertain, a skin biopsy or pathologic examination of a frozen section of freshly sloughed skin can be helpful. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The initial management of SSSS typically involves hospitalization of the patient, intravenous antibiotic therapy, and supportive measures. We suggest intravenous, rather than oral, administration of an antistaphylococcal antibiotic for initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A penicillinase-resistant penicillin, such as <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a> or <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, is usually given as initial therapy. Cephalosporins and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> are alternative treatments. Culture and antibiotic susceptibility testing should be followed to detect the presence of <em>S. aureus</em> strains resistant to the selected therapy. Once clinical improvement occurs, patients may be transitioned to oral antibiotic therapy. (See <a class="local">'Antibiotic therapy'</a> above and <a class="local">'Treatment course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – With appropriate treatment, signs and symptoms of SSSS usually resolve completely within two to three weeks without long-term sequelae. Potential complications include secondary infection, hypovolemia, electrolyte imbalances, sepsis, and rarely death. Recurrence of SSSS is rare. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arora P, Kalra VK, Rane S, et al. Staphylococcal scalded skin syndrome in a preterm newborn presenting within first 24 h of life. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Neubauer HC, Hall M, Wallace SS, et al. Variation in Diagnostic Test Use and Associated Outcomes in Staphylococcal Scalded Skin Syndrome at Children's Hospitals. Hosp Pediatr 2018; 8:530.</a></li><li><a class="nounderline abstract_t">Staiman A, Hsu DY, Silverberg JI. Epidemiology of staphylococcal scalded skin syndrome in U.S. children. Br J Dermatol 2018; 178:704.</a></li><li><a class="nounderline abstract_t">Handler MZ, Schwartz RA. Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol 2014; 28:1418.</a></li><li><a class="nounderline abstract_t">Patel S, Cadwell JB, Lambert WC. Comparison of adult vs. paediatric inpatients with staphylococcal scalded skin syndrome: a retrospective database analysis. Br J Dermatol 2021; 184:767.</a></li><li><a class="nounderline abstract_t">Staiman A, Hsu DY, Silverberg JI. Epidemiology of staphylococcal scalded skin syndrome in US adults. J Am Acad Dermatol 2018; 79:774.</a></li><li><a class="nounderline abstract_t">Lipový B, Brychta P, Chaloupková Z, Suchánek I. Staphylococcal scalded skin syndrome in the Czech Republic: an epidemiological study. Burns 2012; 38:296.</a></li><li><a class="nounderline abstract_t">Li MY, Hua Y, Wei GH, Qiu L. Staphylococcal scalded skin syndrome in neonates: an 8-year retrospective study in a single institution. Pediatr Dermatol 2014; 31:43.</a></li><li><a class="nounderline abstract_t">Lamand V, Dauwalder O, Tristan A, et al. Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains. Clin Microbiol Infect 2012; 18:E514.</a></li><li><a class="nounderline abstract_t">Leung AKC, Barankin B, Leong KF. Staphylococcal-scalded skin syndrome: evaluation, diagnosis, and management. World J Pediatr 2018; 14:116.</a></li><li><a class="nounderline abstract_t">Doudoulakakis A, Spiliopoulou I, Spyridis N, et al. Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections. J Clin Microbiol 2017; 55:2529.</a></li><li class="breakAll">Paller A, Mancini A. Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 5th ed, Elsevier, 2015.</li><li><a class="nounderline abstract_t">Katzman DK, Wald ER. Staphylococcal scalded skin syndrome in a breast-fed infant. Pediatr Infect Dis J 1987; 6:295.</a></li><li><a class="nounderline abstract_t">Pimentel de Araujo F, Tinelli M, Battisti A, et al. An outbreak of skin infections in neonates due to a Staphylococcus aureus strain producing the exfoliative toxin A. Infection 2018; 46:49.</a></li><li><a class="nounderline abstract_t">Paranthaman K, Bentley A, Milne LM, et al. Nosocomial outbreak of staphyloccocal scalded skin syndrome in neonates in England, December 2012 to March 2013. Euro Surveill 2014; 19.</a></li><li><a class="nounderline abstract_t">Brook I. Infectious Complications of Circumcision and Their Prevention. Eur Urol Focus 2016; 2:453.</a></li><li><a class="nounderline abstract_t">Davidson J, Polly S, Hayes PJ, et al. Recurrent Staphylococcal Scalded Skin Syndrome in an Extremely Low-Birth-Weight Neonate. AJP Rep 2017; 7:e134.</a></li><li><a class="nounderline abstract_t">Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7:11.</a></li><li><a class="nounderline abstract_t">Isidori C, Sebastiani L, Cardellini MC, et al. Early Desquamating Perineal Erythema in a Febrile Infant: A Characteristic Clinical Feature of Kawasaki Disease. Int J Environ Res Public Health 2017; 14.</a></li><li><a class="nounderline abstract_t">Webb DV, Stowman AM, Patterson JW. Boric acid ingestion clinically mimicking toxic epidermal necrolysis. J Cutan Pathol 2013; 40:962.</a></li><li><a class="nounderline abstract_t">Lung D, Clancy C. "Boiled lobster" rash of acute boric acid toxicity. Clin Toxicol (Phila) 2009; 47:432.</a></li><li><a class="nounderline abstract_t">Heller E, Murthy AS, Jen MV. A slime of the times: Two cases of acute irritant contact dermatitis from homemade slime. Pediatr Dermatol 2019; 36:139.</a></li><li><a class="nounderline abstract_t">Boyd AS, Seger D, Vannucci S, et al. Mercury exposure and cutaneous disease. J Am Acad Dermatol 2000; 43:81.</a></li><li><a class="nounderline abstract_t">Smith WA, Taintor AR, Kos L, Drolet B. Senna-containing laxative inducing blistering dermatitis in toddlers. Arch Dermatol 2012; 148:402.</a></li><li><a class="nounderline abstract_t">Braunstein I, Wanat KA, Abuabara K, et al. Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome. Pediatr Dermatol 2014; 31:305.</a></li><li><a class="nounderline abstract_t">Hultén KG, Kok M, King KE, et al. Increasing Numbers of Staphylococcal Scalded Skin Syndrome Cases Caused by ST121 in Houston, Texas. Pediatr Infect Dis J 2020; 39:30.</a></li><li><a class="nounderline abstract_t">Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. J Infect Dis 1984; 149:471.</a></li><li><a class="nounderline abstract_t">Chi CY, Wang SM, Lin HC, Liu CC. A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis 2006; 42:181.</a></li><li><a class="nounderline abstract_t">Urata T, Kono M, Ishihara Y, Akiyama M. Adult Staphylococcal Scalded Skin Syndrome Successfully Treated with Multimodal Therapy Including Intravenous Immunoglobulin. Acta Derm Venereol 2018; 98:136.</a></li><li><a class="nounderline abstract_t">Kato T, Fujimoto N, Nakanishi G, et al. Adult staphylococcal scalded skin syndrome successfully treated with plasma exchange. Acta Derm Venereol 2015; 95:612.</a></li><li><a class="nounderline abstract_t">Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case. J Am Acad Dermatol 1994; 30:319.</a></li><li class="breakAll">https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html (Accessed on April 05, 2019).</li><li><a class="nounderline abstract_t">Mishra AK, Yadav P, Mishra A. A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates. Open Microbiol J 2016; 10:150.</a></li></ol></div><div id="topicVersionRevision">Topic 114922 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670002" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Staphylococcal scalded skin syndrome in a preterm newborn presenting within first 24 h of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139766" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Variation in Diagnostic Test Use and Associated Outcomes in Staphylococcal Scalded Skin Syndrome at Children's Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29077993" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of staphylococcal scalded skin syndrome in U.S. children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24841497" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Staphylococcal scalded skin syndrome: diagnosis and management in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33217773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of adult vs. paediatric inpatients with staphylococcal scalded skin syndrome: a retrospective database analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29902545" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of staphylococcal scalded skin syndrome in US adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22035884" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Staphylococcal scalded skin syndrome in the Czech Republic: an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557104" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Staphylococcal scalded skin syndrome in neonates: an 8-year retrospective study in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23078129" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508362" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Staphylococcal-scalded skin syndrome: evaluation, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592549" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592549" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3575014" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Staphylococcal scalded skin syndrome in a breast-fed infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29110142" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An outbreak of skin infections in neonates due to a Staphylococcus aureus strain producing the exfoliative toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25166346" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nosocomial outbreak of staphyloccocal scalded skin syndrome in neonates in England, December 2012 to March 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723479" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Infectious Complications of Circumcision and Their Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674637" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recurrent Staphylococcal Scalded Skin Syndrome in an Extremely Low-Birth-Weight Neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15777108" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxic shock syndrome in children: epidemiology, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28665334" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early Desquamating Perineal Erythema in a Febrile Infant: A Characteristic Clinical Feature of Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992546" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Boric acid ingestion clinically mimicking toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19492934" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : "Boiled lobster" rash of acute boric acid toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30152559" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A slime of the times: Two cases of acute irritant contact dermatitis from homemade slime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mercury exposure and cutaneous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431792" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Senna-containing laxative inducing blistering dermatitis in toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033633" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725120" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increasing Numbers of Staphylococcal Scalded Skin Syndrome Cases Caused by ST121 in Houston, Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6715902" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355327" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815266" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adult Staphylococcal Scalded Skin Syndrome Successfully Treated with Multimodal Therapy Including Intravenous Immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519855" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adult staphylococcal scalded skin syndrome successfully treated with plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8294590" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8294590" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27651848" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
